Therapeutic strategies targeting cholesterol metabolism, such as MVK gene knockout and HMGCR inhibitors like simvastatin, have demonstrated potential in reactivating CD8+ T cells and boosting anti‐tumour immune responses in CRC. The gene discussed is CD8A; the disease is neoplasm.